Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN
- 93 Downloads
Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.
KeywordsGlioblastoma multiforme Recurrent disease Epidermal growth factor receptor PTEN Tyrosine kinase inhibitors
Unable to display preview. Download preview PDF.
- 24.Vogelbaum MA, Peereboom D, Stevens GHJ et al (2004) Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme. Results of a phase II study. Neuro Oncol 6:384 (Abstr TA-59)Google Scholar
- 28.Chakravarti A, Loeffler JS, Dyson NJ et al (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primaty human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200–207PubMedGoogle Scholar
- 32.Janmaat ML, Kruyt FA, Rodríguez JA et al (2003) Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer: limited antiproliferative effect and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316–2326PubMedGoogle Scholar
- 37.Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101–112PubMedGoogle Scholar
- 38.Sampaio C, Dance M, Montagner A et al (2008) Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition. Mol Cell Biol 28:587–600CrossRefPubMedGoogle Scholar